Company name
GliaPharm SA
Company profile
GliaPharm develops novel treatments to treat neurological conditions. Through its platform it has designed a pipeline of first-in-class compounds, that selectively modulate astrocyte targets involved in brain metabolism. Its lead molecule , GP-119, has completed IND/CTA enabling studies and is planned to enter clinical trials in H2 of 2026. It is effective in models of Alzheimer’s disease, GLUT1 Deficiency Syndrome and other neurological conditions.
Date, time and room information
Tuesday, May 5, 14:00 - 14:15, room Singapore
Category
Emerging biotech company
Title of the presentation
Targeting Brain Energy Metabolism Treat Neurological Diseases
Speaker information
| Name | Position | Institution |
|---|---|---|
| Ambroise Magistretti | Co-CEO, Co-Founder | GliaPharm SA |
